ArticleBiosafety and health2026
SFTS exerts an underrecognized disease burden and socioeconomic effect in East Asia.
Article in Biosafety and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne virus that poses a growing public health concern, especially in East Asia. However, its global distribution, disease burden, and economic impact remain insufficiently characterized. In this study, we have systematically reviewed literature databases, GenBank, and official reports to provide a comprehensive overview of global SFTSV detections. Seropositive or nucleic acid-positive individuals have been reported not only in East Asia, but also in Thailand, Myanmar, Vietnam, Pakistan, and Kenya. In addition, SFTSV has been identified in ten animal orders and in both ticks and other arthropod vectors. Severe fever with thrombocytopenia syndrome (SFTS) incidence, mortality, and disability-adjusted life years (DALYs) have shown an increasing trend across East Asia. China recorded the highest absolute DALYs, exceeding those of other neglected tropical diseases, such as dengue fever. The average cost per SFTS case was substantial, exceeding 75 % of the annual per capita disposable income in China, and 41.38 % and 23.52 % in Japan and South Korea, respectively. These findings highlight the expanding distribution of SFTSV and its significant per-case disease and economic burden in East Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.